Insmed Inc
Company Profile
Business description
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Contact
700 US Highway 202/206
BridgewaterNJ08807
USAT: +1 908 977-9900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,664
Stocks News & Analysis
stocks
The best global tech stocks to buy
stocks
Earnings margins to improve for mining specialist
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,114.30 | 79.50 | -0.86% |
| CAC 40 | 8,317.98 | 11.83 | 0.14% |
| DAX 40 | 26,007.63 | 1.10 | 0.00% |
| Dow JONES (US) | 52,788.63 | 625.62 | -1.17% |
| FTSE 100 | 10,811.66 | 10.47 | -0.10% |
| HKSE | 25,317.18 | 95.94 | -0.38% |
| NASDAQ | 26,427.34 | 79.65 | -0.30% |
| Nikkei 225 | 65,269.33 | 1,130.52 | -1.70% |
| NZX 50 Index | 13,792.90 | 149.93 | -1.08% |
| S&P 500 | 7,680.66 | 37.94 | -0.49% |
| S&P/ASX 200 | 8,920.80 | 82.20 | -0.91% |
| SSE Composite Index | 3,940.55 | 7.85 | 0.20% |